Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Inventory (2020 - 2025)

Bioventus (BVS) has disclosed Inventory for 6 consecutive years, with $82.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory fell 11.07% year-over-year to $82.2 million, compared with a TTM value of $82.2 million through Dec 2025, down 11.07%, and an annual FY2025 reading of $82.2 million, down 11.07% over the prior year.
  • Inventory was $82.2 million for Q4 2025 at Bioventus, down from $96.3 million in the prior quarter.
  • Across five years, Inventory topped out at $97.6 million in Q3 2023 and bottomed at $34.0 million in Q3 2021.
  • Average Inventory over 5 years is $80.0 million, with a median of $90.7 million recorded in 2023.
  • The sharpest move saw Inventory rose 7.75% in 2023, then fell 11.07% in 2025.
  • Year by year, Inventory stood at $36.6 million in 2021, then surged by 131.82% to $84.8 million in 2022, then grew by 7.75% to $91.3 million in 2023, then grew by 1.25% to $92.5 million in 2024, then dropped by 11.07% to $82.2 million in 2025.
  • Business Quant data shows Inventory for BVS at $82.2 million in Q4 2025, $96.3 million in Q3 2025, and $94.0 million in Q1 2025.